Brought to you by 
Oscient sells nearly $144mm in convertible notes
08 Jun 2004
Executive Summary
Oscient Pharmaceuticals Corp. (changed name from Genome Therapeutics upon its recent merger with GeneSoft Pharmaceuticals) has closed a private placement of $143.75mm in 3.5% senior convertible notes due 2011. The total includes the investors' exercise of their option to purchase additional notes beyond the basic investment.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oscient sells nearly $144mm in convertible notes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice